Abstracts tagged "Outcome measures"

Abstract Number: 1473 • 2012 ACR/ARHP Annual Meeting
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Giuseppina Abignano¹, Giovanna Cuomo², Maya H. Buch³, William M. Rosenberg⁴, Gabriele Valentini⁵, Paul Emery⁶ and Francesco Del Galdo⁷, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴Centre for Hepatology - UCL, London, United Kingdom, ⁵Rheumatology/Int Med, Second University of Naples, Rheumatology Unit, Naples, Italy, ⁶Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP),…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Gerd Burmester¹, Désirée van der Heijde², Vibeke Strand³, Cristiano A. F. Zerbini⁴, Carol A. Connell⁵, Charles A. Mebus⁵, Samuel H. Zwillich⁶, John D. Bradley⁵, David Gruben⁵ and Gene Wallenstein⁵, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
Abstract Number: 1155 • 2012 ACR/ARHP Annual Meeting
A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis
Sheila T. Angeles-Han¹, Steven Yeh², Courtney McCracken¹, Larry B. Vogler³, Kelly A. Rouster-Stevens⁴, Christine W. Kennedy⁵, Kirsten Jenkins⁶, Matthew Kent³, Scott Lambert⁷, Carolyn Drews-Botsch⁸ and Sampath Prahalad⁹, ¹Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Dept of Pediatrics, Emory Univ School of Medicine, Atlanta, GA, ⁴Pediatric Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁵Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁶Children's Healthcare of Atlanta, Atlanta, GA, ⁷Ophthalmology, Emory Univ School of Medicine, Atlanta, GA, ⁸Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁹Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Studies on outcomes of children with juvenile idiopathic arthritis-associated uveitis (JIA-U) focus on the clinical ocular exam and physical disability secondary to arthritis. This…
Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting
Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry
Bente Glintborg¹, Mikkel Østergaard², Niels Steen Krogh³, Martin Dehn Andersen⁴, Ulrik Tarp⁴, Anne Gitte Loft⁴, Hanne M. Lindegaard⁵, Mette Holland-Fischer⁶, Henrik Nordin⁴, Dorte Vendelbo Jensen⁴ and Merete L. Hetland², ¹Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…
Abstract Number: 1090 • 2012 ACR/ARHP Annual Meeting
A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Replacement Patients
Jamie E. Collins¹, Benjamin N. Rome¹, Vladislav Lerner¹, Jeffrey N. Katz² and Elena Losina¹, ¹Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Range of motion (ROM) is an important component of the assessment of total knee replacement (TKR) outcome. Traditionally, ROM is measured by a clinician…
Abstract Number: 2105 • 2012 ACR/ARHP Annual Meeting
Significant Correlation Between ACR/EULAR Remission Criteria and a Simplified Measure Using RAPID3 and Careful Joint Examination without a Formal Joint Count
Martin J. Bergman¹, Isabel Castrejón² and Theodore Pincus², ¹Taylor Hospital, Ridley Park, PA, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Definitions for the classification of “remission” have been proposed by ACR/EULAR: Boolean and SDAI1 swollen joint can be performed without interfering with usual patient interactions,…
Abstract Number: 1016 • 2012 ACR/ARHP Annual Meeting
The Effect of Evaluation Variability At the Unit of Measurement On the Reliability of Omeract Ramris and Van Der Heijde-Modified Sharp Score
Ruben Tavares¹, Naveen Parasu², Karen Finlay³, Erik Jurriaans³, Hao Wu¹, Karen A. Beattie⁴, Maggie Larche⁵, Lawrence E. Hart⁶, William G. Bensen⁷, Raja S. Bobba⁵, Alfred A. Cividino⁴, Colin E. Webber⁸, Jean-Eric Tarride⁹ and Jonathan D. Adachi¹⁰, ¹McMaster University, Hamilton, ON, Canada, ²Radiology, Hamilton Health Sciences, Hamilton, ON, ³Radiology, Hamilton Health Sciences, Hamilton, ON, Canada, ⁴Medicine, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Medicine (Rheumatology), St. Joseph's Health Care, Hamilton, ON, Canada, ⁷Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁸Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, ON, Canada, ⁹Clinical Epidemiology and Biostatistics (CE&B) and Economics, Programs for Assessment of Technology in Health (PATH) Research Institute, Hamilton, ON, Canada, ¹⁰St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) and van der Heijde-modified Sharp score (vdHSS) are recognized semi-quantitative measures…
Abstract Number: 2118 • 2012 ACR/ARHP Annual Meeting
Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, George A. Wells⁴, Joan M. Bathon⁵, Clifton O. Bingham III⁶, Vivian P. Bykerk⁷, Mikkel Ostergaard⁸, Hilde B. Hammer⁹, Maarten Boers¹⁰, Paul Peter Tak¹¹, Oliver M. FitzGerald¹², Christopher T. Ritchlin¹³, Dafna D. Gladman¹⁴, Philip J. Mease¹⁵, Dirkjan van Schaardenburg¹⁶, Marina Backhaus¹⁷, Bernard Combe¹⁸, Gianfranco Ferraccioli¹⁹ and Anthony Marotta²⁰, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada, ⁵Columbia University, New York, NY, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ¹³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Swedish Rheumatology Research Group, Seattle, WA, ¹⁶Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁷Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹⁸Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The OMERACT soluble biomarker sub-committee has published validation criteria related to truth, discrimination and feasibility for biomarkers reflecting structural damage1. The large majority of…
Abstract Number: 869 • 2012 ACR/ARHP Annual Meeting
Concepts Which Determine Health in a Positive Way Are Important to People with Rheumatoid Arthritis and Are Covered by Some Patient-Reported Outcome Instruments
Mona Dür¹, Michaela Coenen², Josef S. Smolen³ and Tanja A. Stamm⁴, ¹Internal Medicine III Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medical lnformatics, Biometry and Epidemiology, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-University, Munich, Germany, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease that has a major impact on functioning, health and well-being. Concepts which determine health in a positive…
Abstract Number: 2100 • 2012 ACR/ARHP Annual Meeting
Relative, Reliability-Adjusted Diagnostic Test Accuracy of Erosion Detection Between Magnetic Resonance Imaging and Radiography in Rheumatoid Arthritis
Ruben Tavares¹, Naveen Parasu², Karen Finlay², Erik Jurriaans², Hao Wu¹, Karen A. Beattie³, Maggie Larche⁴, Lawrence E. Hart⁵, William G. Bensen⁶, Raja S. Bobba⁴, Alfred A. Cividino³, Colin E. Webber⁷, Jean-Eric Tarride⁸ and Jonathan D. Adachi⁹, ¹McMaster University, Hamilton, ON, Canada, ²Radiology, Hamilton Health Sciences, Hamilton, ON, Canada, ³Medicine, McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Medicine (Rheumatology), St. Joseph's Health Care, Hamilton, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁷Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, ON, Canada, ⁸Clinical Epidemiology and Biostatistics (CE&B) and Economics, Programs for Assessment of Technology in Health (PATH) Research Institute, Hamilton, ON, Canada, ⁹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: In rheumatoid arthritis (RA), erosion detection on radiography (X-ray) compared to magnetic resonance imaging (MRI) is characterized by low sensitivity and high specificity. This…
Abstract Number: 710 • 2012 ACR/ARHP Annual Meeting
Optical Density Measure of the Papillary Dermis Discriminates As Abnormal Clinically Uninvolved Skin in Systemic Sclerosis and Correlates with Severity of Skin Thickness
Giuseppina Abignano¹, Sibel Z. Aydin², Concepcion Castillo-Gallego³, Daniel Woods⁴, Adam Meekings⁵, Dennis McGonagle⁶, Paul Emery⁷ and Francesco Del Galdo⁸, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Michelson Diagnostics Ltd, Kent, United Kingdom, ⁵Michelson Diagnostics Ltd, Kent, United Kingdom, Kent, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁸Musculoskeletal Diseases, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Skin involvement in systemic sclerosis (SSc) is often primary outcome in clinical trials and its severity inversely correlates with prognosis. Nevertheless, an objective quantitative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].